NxStage Medical Inc. (NASDAQ:NXTM) shares were down 1.6% during trading on Monday . The stock traded as low as $25.02 and last traded at $25.06, with a volume of 407,062 shares changing hands. The stock had previously closed at $25.46.

A number of research analysts recently commented on NXTM shares. Northland Securities raised shares of NxStage Medical from a “market perform” rating to an “outperform” rating and set a $25.00 price target for the company in a report on Tuesday, June 28th. Zacks Investment Research raised shares of NxStage Medical from a “hold” rating to a “buy” rating and set a $27.00 price target for the company in a report on Tuesday, August 9th. Canaccord Genuity increased their price target on shares of NxStage Medical from $22.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, August 2nd. Piper Jaffray Cos. reaffirmed a “buy” rating and issued a $21.00 price target on shares of NxStage Medical in a report on Friday, June 3rd. Finally, BTIG Research reissued a “buy” rating and issued a $27.00 price objective on shares of NxStage Medical in a research note on Tuesday, June 7th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $26.43.

The firm’s market capitalization is $1.62 billion. The firm’s 50-day moving average is $22.62 and its 200-day moving average is $18.23.

NxStage Medical (NASDAQ:NXTM) last posted its quarterly earnings data on Thursday, August 4th. The medical device company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.01. The company earned $92.20 million during the quarter, compared to analyst estimates of $89.44 million. During the same period in the previous year, the company earned ($0.08) EPS. The business’s revenue for the quarter was up 14.8% compared to the same quarter last year. Analysts anticipate that NxStage Medical Inc. will post ($0.12) earnings per share for the current fiscal year.

A number of large investors have modified their holdings of NXTM. Morgan Stanley increased its stake in shares of NxStage Medical by 1.3% in the fourth quarter. Morgan Stanley now owns 67,174 shares of the medical device company’s stock worth $1,472,000 after buying an additional 874 shares during the last quarter. Rhumbline Advisers increased its stake in shares of NxStage Medical by 8.3% in the fourth quarter. Rhumbline Advisers now owns 68,426 shares of the medical device company’s stock worth $1,499,000 after buying an additional 5,240 shares during the last quarter. Trexquant Investment LP increased its stake in shares of NxStage Medical by 142.4% in the fourth quarter. Trexquant Investment LP now owns 57,700 shares of the medical device company’s stock worth $1,264,000 after buying an additional 33,900 shares during the last quarter. Wells Fargo & Company MN increased its stake in shares of NxStage Medical by 6.5% in the fourth quarter. Wells Fargo & Company MN now owns 1,450,307 shares of the medical device company’s stock worth $31,777,000 after buying an additional 88,286 shares during the last quarter. Finally, Jennison Associates LLC increased its stake in shares of NxStage Medical by 32.9% in the fourth quarter. Jennison Associates LLC now owns 1,395,174 shares of the medical device company’s stock worth $30,568,000 after buying an additional 345,394 shares during the last quarter.

NxStage Medical, Inc is a medical device company. The Company is engaged in the development, manufacturing and marketing of products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. The Company’s products include the System One, Streamline Blood Tubing Sets and AV Fistula and Apheresis Needles.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.